ATE517346T1 - Gpr18 als biomarker für th1-vermittelte immunantwort - Google Patents

Gpr18 als biomarker für th1-vermittelte immunantwort

Info

Publication number
ATE517346T1
ATE517346T1 AT06724680T AT06724680T ATE517346T1 AT E517346 T1 ATE517346 T1 AT E517346T1 AT 06724680 T AT06724680 T AT 06724680T AT 06724680 T AT06724680 T AT 06724680T AT E517346 T1 ATE517346 T1 AT E517346T1
Authority
AT
Austria
Prior art keywords
gpr18
biomarker
immune response
mediated immune
mediated
Prior art date
Application number
AT06724680T
Other languages
English (en)
Inventor
Gudrun Werner
Guenther Lametschwandtner
Claudia Guenther
Herrera Jose Carballido
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE517346T1 publication Critical patent/ATE517346T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06724680T 2005-05-03 2006-05-02 Gpr18 als biomarker für th1-vermittelte immunantwort ATE517346T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0508988.3A GB0508988D0 (en) 2005-05-03 2005-05-03 Organic compounds
PCT/EP2006/004096 WO2006117194A2 (en) 2005-05-03 2006-05-02 Gpr18 as a biomaker for th1 mediated immune response

Publications (1)

Publication Number Publication Date
ATE517346T1 true ATE517346T1 (de) 2011-08-15

Family

ID=34674238

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06724680T ATE517346T1 (de) 2005-05-03 2006-05-02 Gpr18 als biomarker für th1-vermittelte immunantwort

Country Status (7)

Country Link
US (1) US20090208997A1 (de)
EP (1) EP1880219B1 (de)
JP (1) JP2008540361A (de)
AT (1) ATE517346T1 (de)
ES (1) ES2370035T3 (de)
GB (1) GB0508988D0 (de)
WO (1) WO2006117194A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5433189B2 (ja) * 2007-09-28 2014-03-05 承一 尾崎 Mpo−anca関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法
CN108241054B (zh) * 2017-12-26 2021-03-12 天津市中西医结合医院(天津市南开医院) 检测g蛋白偶联受体18的试剂在制备败血症诊断及病程监测和预后判断试剂中表达的应用
US20240108689A1 (en) * 2021-01-22 2024-04-04 The Brigham And Women's Hospital, Inc. Modulation of a pathogenic phenotype in th1 cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP1571968A4 (de) * 2002-04-16 2007-10-17 Genentech Inc Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
US20040018522A1 (en) * 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis

Also Published As

Publication number Publication date
GB0508988D0 (en) 2005-06-08
US20090208997A1 (en) 2009-08-20
JP2008540361A (ja) 2008-11-20
WO2006117194A2 (en) 2006-11-09
EP1880219A2 (de) 2008-01-23
ES2370035T3 (es) 2011-12-12
EP1880219B1 (de) 2011-07-20
WO2006117194A3 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
MX2009013194A (es) Proteinas de fusion del receptor para productos finales de glicacion avanzada.
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
NZ735173A (en) Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
EA201490832A1 (ru) Биомаркеры, имеющие прогностическое значение в отношении ответа на лечение активатором альфа 7 никотиновых ацетилхолиновых рецепторов
EA201000844A1 (ru) Связывающие wise агенты и эпитопы
EA201101520A1 (ru) Способы диагностики онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
NO20091064L (no) Antistoffer mot IL-17A
EA200901621A1 (ru) Индукция толерогенного фенотипа у зрелых дендритных клеток
IN2014MN01642A (de)
BR112014013150A2 (pt) benzimidazoles e benzopirazoles substituídas como antagonistas de ccr(4)
DOP2011000274A (es) Proteinas de union a il-17
ATE469895T1 (de) Cgrp-rezeptorantagonisten
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
EA200800835A1 (ru) Циклопропиламины в качестве модуляторов рецептора гистамина н
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
ATE554396T1 (de) Diagnose- und therapiewerkzeuge für krankheiten, die die gefässfunktion verändern
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
DE602007004999D1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
FR2942798B1 (fr) Peptides utilisables pour le traitement de la leucemie lymphoide chronique
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties